Potential human immunotherapeutics for plague

Area of Science:

• Immunology
• Microbiology
• Infectious Diseases

Background:

• Plague, caused by Yersinia pestis, remains a significant public health concern in endemic regions.
• Effective immunotherapeutics are crucial for controlling Yersinia pestis outbreaks.
• Monoclonal antibodies targeting Yersinia pestis antigens are a promising therapeutic strategy.

Purpose of the Study:

• To evaluate the protective efficacy of two monoclonal antibodies (Mab7.3 and Mab 29.3) against Yersinia pestis infection.
• To assess the efficacy of these antibodies when administered before and after infection.
• To contribute to the development of novel immunotherapies for plague.

Main Methods:

• A murine model of bubonic plague was established using a clinical isolate of Yersinia pestis (10-21/S) from Madagascar.
• Mice were infected and treated with Mab7.3 or Mab 29.3 intraperitoneally at 24 hours prior to or 24 hours post-infection.
• Protective efficacy was determined by survival rates and clinical outcomes.

Main Results:

• Mab7.3 demonstrated complete protection against Yersinia pestis infection, consistent with previous studies.
• Mab 29.3 showed significant protective efficacy, with 4 out of 5 mice surviving in both pre- and post-infection treatment groups.
• This study provides the first in vivo demonstration of Mab 29.3's efficacy.

Conclusions:

• Both Mab7.3 and Mab 29.3 exhibit potent protective efficacy against Yersinia pestis infection in a murine model.
• Mab7.3, currently undergoing humanization, shows great potential as a human immunotherapeutic for plague.
• These findings support the continued development of monoclonal antibodies for plague prevention and treatment, particularly in endemic areas.